Article

Microperimetry Feasible for AMD Assesment Despite Mixed Research Results

Author(s):

There is some promising evidence for the use of microperimetry in functionally assessing AMD, despite research results being limited.

Nicola Cassels, BSc

A review focusing on the use of microperimetry as an imaging technique for evaluation of age-related macular degeneration (AMD) reported mixed results with the use of the novel technique based on the limitations of current research.

Lead study author Nicola Cassels, BSc, and corresponding author John M. Wild, PhD, DSc, with the Cardiff Center for Vision Sciences at Cardiff University in the UK, stated that while current research on the use of microperimetry as a stand-alone measure of functional assessment in AMD is limited, future research utilizing microperimetry and spectral domain optical coherence tomography (SD-OCT) could help provide a multimodal representation of AMD useful in developing of a "topographical classification system for all stages of AMD."

In their systematic review, Cassels, Wild and colleagues analyzed 52 articles focused on efficacy and imaging outcomes of microperimetry and/or the relationship between microperimetry outcomes AMD and other measures of visual function. Their review data determined that "over half the articles had "limitations relating to the quality of the microperimetry outcome (n = 18) and/or to the reporting of the SD-OCT methods and analysis (n = 11)" and that the reporting of outcomes in published research articles was "generally poor, particularly in regard to the description of the stimulus program."

Cassels wrote that microperimetry, or fundus related perimetry, is "similar to standard automated perimetry in that it measures the differential light sensitivity (DLS)" in patients to measure visual field function, but that one of the potential benefits of microperimetry is that the technique may be better able to accurately evaluate macular function in patients with retinal disease such as AMD. This, according to Cassels, is because microperimetry uses an "eye tracking system to correct the position of the stimulus for any changes in fixation."

The ability of microperimetry to correct, Cassels argues, makes it potentially useful in late stages of AMD when patients have difficulty fixating on visual stimulus. Theoretically, the technique might offer a way to assess visual function in AMD patients in a manner "more indicative" of functional loss than simple visual acuity (VA) testing, which the researchers stated is often insufficiently sensitive to detect the early stages of functional loss in AMD, she wrote.

The researchers argued that the limits of microperimetry studies suggests that it is currently "questionable as to whether microperimetry can correctly classify AMD disease severity" in part due to an inconsistent range of reporting methods and measurements which complicates comparisons between studies, the lack of a "robust statistical analysis software package for microperimetry," and a lack of clinical research into "dark adaptation in early AMD."

Despite their mixed findings during the review, Cassels, Wild and colleagues suggest that there is some promising evidence for "the use of microperimetry in the functional assessment of AMD." Microperimetry offers, according to review findings, "detailed topographic information relative to traditional measures of foveal function" and has proven superior to traditional VA in early AMD in some studies, but Cassels and Wild caution that more consistent research is needed to determine the true clinical value of microperimetry as a means to assess visual function in AMD.

Cassels and Wild ultimately suggest that although microperimetry alone is of indeterminate utility in connection with AMD given the technique's limitations and the limitations of the research produced in current studies, that the use of microperimetry in addition to other imaging modalities such as SD-OCT could aid researchers in developing a multimodal topographical classification system for AMD in all stages, something the authors write "represents an exciting prospect."

The review, "The use of microperimetry in assessing visual function in age-related macular degeneration" was published in the Survey of Ophthalmology.

Related Coverage >>>

Low Luminance Questionnaire Linked to Functional Measures of AMD

DEX Implant Data Helps Guide Treatment for DME

Safety, Tolerability Increases Post-Bevacizumab Injection in Intraocular Pressure

Related Videos
Quan Dong Nguyen, MD: Phase 2 Neptune Trial Advances Brepocitnib for Uveitis | Image Credit: Stanford University
Charles C. Wykoff, MD, PhD: Phase 1b/2a Results on Restoret for DME, nAMD | Image Credit: Retina Consultants of Texas
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Arshad Khanani, MD: First Results from Fellow Eye Dosing of RGX-314 in nAMD | Image Credit: Sierra Eye Associates
Joel A. Pearlman, MD, PhD: Phase 2a Data on Oral RZ402 for DME | Image Credit: Retina Consultants Medical Group
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
© 2024 MJH Life Sciences

All rights reserved.